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Anthracyclines are frequently used for the treatment of
breast cancer and topoisomerase II alpha (TOP2A) is
considered to be the molecular target. Numerous studies
have evaluated the predictive value of TOP2A using dif-
ferent methodological approaches and inconsistent re-
sults have been reported. Indeed, the correlation be-
tween techniques for the assessment of TOP2A status
has not been well evaluated. In this study, we deter-
mined TOP2A status in 61 breast tumor samples by real-
time PCR, DNA microarrays, immunohistochemistry
(IHC), and fluorescence in situ hybridization (FISH),
and then evaluated these results with clinical-patholog-
ical features and breast cancer intrinsic subtypes. First,
we observed a statistical significant correlation of
TOP2A gene expression between real-time PCR and mi-
croarrays (Pearson coefficient, 0.816; P < 0.001), and
both predicted TOP2A IHC results fairly well (area un-
der the curve > 0.74). In contrast, poor agreement be-
tween FISH and IHC data was observed (k: 0.134). Sec-
ondly, TOP2A expression was found significantly
associated with cell proliferation, and with the highly
proliferative Luminal B, Her2-enriched and Basal-likeintrinsic subtypes. In conclusion, TOP2A expression in
breast cancer was associated with high proliferation
and aggressive tumor subtypes and appears to be inde-
pendent of its amplification status. All of these features
should be taken into consideration when assessing
the predictive value of TOP2A for anthracycline-based
chemotherapy. (Am J Pathol 2011, 178:1453–1460; DOI:
10.1016/j.ajpath.2010.12.042)
Anthracyclines are some of the most powerful agents avail-
able for the treatment of breast cancer and are frequently
used in the adjuvant setting. However, anthracyclines are
associated with severe adverse effects, such as cardiac tox-
icity1 and bone marrow dysfunction, including acute leukemia
and myelodysplasia.2 Therefore, there is a need to identify the
subset of patients who might benefit from these drugs.
The mechanism of action of these compounds is related
to the inhibition of the nuclear enzyme DNA topoisomerase
II (Topo II),3 although other antitumor mechanisms have
also been described.4 Topoisomerase II is an important
enzyme for cell division because it releases torsional stress
in double-stranded DNA by inducing transient breaks that
are then subsequently resealed.5 The catalytic activity of
Topo II in mammalian cells is mediated by two isoforms [ie,
Topo II  (TOP2A) and Topo II ].6 In vitro studies7–10 have
suggested that sensitivity to Topo II inhibitors is dependent
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Cells with a low concentration of TOP2A protein are less
sensitive to Topo II–inhibiting drugs versus cells containing
a high concentration of TOP2A. Interestingly, the TOP2A
gene itself is frequently found coamplified with v-erb-b2
erythroblastic leukemia viral oncogene homolog 2, neuro/
glioblastoma derived oncogene homolog (avian) (ERBB2)
in human breast cancer cells,11 and several studies12–16
have shown that anthracycline-containing regimens im-
prove survival in women with ERBB2-positive breast cancer.
Numerous retrospective studies have investigated the
predictive value of TOP2A using different methods. Some
of these approaches have focused on determining
TOP2A expression,17,18 whereas others have evaluated
TOP2A copy number.19,20 In any case, the results of
these studies are contradictory and it is still unclear
whether investigating TOP2A provides useful clinical in-
formation concerning anthracycline benefit. Current tech-
niques for measuring TOP2A are not standardized, which
may account, at least partly, for these apparently contra-
dictory results. In addition, the agreement among tech-
niques and the correlation between TOP2A expression
values measured by different methods is also not well
established. On the other hand, TOP2A is considered a
surrogate marker of cell proliferation and its expression
has been associated with high tumor grade21,22 and the
absence of hormone receptors,23 suggesting that over-
expression of TOP2A could be characteristic of a specific
type of breast tumor. Investigation of the predictive sig-
nificance of TOP2A for anthracycline-containing regi-
mens requires knowing the correlation between different
methods and the characterization of TOP2A-expressing
tumors to control potential confounding factors.
The aim of this study was to evaluate the status of
TOP2A in breast cancer tumors by four different methods
[ie, fluorescence in situ hybridization (FISH), gene ex-
pression via DNA microarrays, gene expression via real-
time PCR (Q-PCR), and immunohistochemistry (IHC)].
We also sought to assess the correlation and agreement
among these techniques when classifying the tumors as
TOP2A positive or negative. In addition, TOP2A status
was correlated to clinical features, such as cell prolifera-
tion, hormone receptor status, and breast cancer intrinsic
subtypes, that identified many significant correlations.
Material and Methods
Study Population
Tumor biopsy specimens were obtained from a set of 61
pretreated patients diagnosed as having locally advanced
breast cancer; these patients participated in a neoadjuvant
clinical trial (registered at the following Web site: http://www.
clinicaltrials.gov; identifier NCT00123929). The clinical trial
was approved by the Hospital Clínico San Carlos Ethics
Committee, Madrid, Spain. Briefly, eligibility criteria in-
cluded the following: women aged between 18 and 78
years; clinical stage IIB, IIIA, or IIIB breast cancer; and
palpable breast tumors not amenable to breast-preserv-
ing surgery. Before the start of the trial, an informedconsent was obtained from every patient. A total of 226
registered patients were enrolled in the trial; 204 un-
derwent a complete evaluation. No significant differ-
ences were observed between the subset of 61 pa-
tients and the whole cohort of 226 patients. Clinical and
pathological characteristics of each of the 61 patients
are available in Supplemental Table S1 (at http://ajp.
amjpathol.org).
RNA Isolation and Microarray Expression
Profiling
Total RNA was extracted from tumor biopsy specimens
using a kit (Qiagen RNeasy Mini Kit; Qiagen Inc., Valen-
cia, CA), following the instructions of the manufacturer.
The biopsy specimens were obtained before neoadju-
vant chemotherapy. To check cellularity, an H&E image
was obtained from all tumors; only samples with more
than 80% tumor cells were used. The amount of RNA was
assessed with a device (Nanodrop ND-1000 UV Spec-
trophotometer; Thermo Fisher Scientific, Wilmington, DE).
RNA integrity was assessed using a kit (RNA 6000 Nano
Chip kit), followed by analysis (Bioanalyzer 2100; Agilent
Technologies, Santa Clara, CA). Whole human genome
oligo 4  44 microarrays (Agilent Technologies) were
hybridized after low RNA input fluorescence amplification
of tumor total RNA, according to the manufacturer’s pro-
tocol. Arrays were scanned (GenePix 4000B scanner;
Molecular Devices Corporation, Sunnyvale, CA), ana-
lyzed using software (GenePix 5.1), and uploaded into a
University of North Carolina microarray database, in
which a Lowess normalization of the log2 ratio (Cyanine
5/Cyanine 3) intensity values is automatically performed.
For all analyses, genes were filtered by requiring the
Lowess-normalized intensity values in both channels to
be greater than 10; only genes that reported values in
70% or more of the samples were included. The genes
were median centered across all samples. Breast cancer
subtypes were assigned as described by Parker et al.24
In addition, the recently identified subtype named Clau-
din-low was assigned using a separate centroid-based
predictor25; therefore, tumors were categorized into Lu-
minal A, Luminal B, Basal-like, Her2-enriched, Claudin-
low, and Normal-like. The primary microarray data pre-
sented in this study are available in the Gene Expression
Omnibus database (accession No. GSE21997).
Q-PCR Analysis
Total RNA, 200 ng, was used as a template to obtain
first-strand cDNA using a system (SuperScript First-
Strand Synthesis System for RT-PCR; Invitrogen, Pars-
ley, UK), following the manufacturer’s instructions. To
determine that cDNA was synthesized, the first-strand
cDNA was further amplified by conventional PCR using
primers for -actin, as previously described.26 Real-
time PCR was performed using gene expression as-
says (TaqMan; Applied Biosystems, Foster City, CA)
and a PCR system (ABI PRISM 7900HT Fast Real Time
PCR System; Applied Biosystems). Briefly, 4 L of
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primers, probes labeled with 5,6 carboxifluoresceina
reporter dye (assay Hs00172214_m1), 1 L of 20
human -actin primers, and probes labeled with VIC-
reported dye (TaqMan endogenous control, part
4326315E; Applied Biosystems), 10 L of mix (TaqMan
Universal PCR Mastermix), and 4 L of RNase-free
water. Human -actin served as an endogenous con-
trol to normalize the TOP2A mRNA levels in the subse-
quent quantitative analysis. The PCR conditions were
those recommended by the manufacturer. A pool of
RNA from 11 breast tissue samples of healthy individ-
uals who underwent cosmetic or plastic surgery was
used as a control. Each sample was measured in trip-
licate. The data were analyzed by the comparative Ct
method, in which the amount of TOP2A, normalized to
-actin and relative to control, is given as follows:
2(Ct sample  Ct control). Tumors that yielded values of
two or greater were considered as TOP2A positive.
IHC and Tumor Grading
Paraffin-embedded tumor samples from core biopsy
specimens were evaluated by IHC analysis for TOP2A
(TOP2A-mouse monoclonal antibody Novocastra Leica-
TopoIIA, clone 3F6, 1:40; Leica Microsystems, Wetzlar,
Germany); estrogen receptor (ER) (clone 1D5, 1:35;
Dako Cytomation, Glostrup, Denmark), progesterone re-
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Histological feature








II 40 9 0.76
III 21 6
Ki-67
Low 18 3 0.52
High 43 12
Estrogen receptor
Positive 36 12 0.07
Negative 25 3
Progesterone receptor
Positive 37 10 0.76
Negative 24 5
ERBB2 status
Positive 19 8 0.05†
Negative 42 7
CNA, copy number alteration.
*Data are given as the mean (SD).
†Significant difference.ceptor (clone PgR 636, 1:50; Dako Cytomation), and
Ki-67 (clone MIB-1, 1:75; Dako Cytomation). After incu-
bation with the primary antibodies, immunohistochemical
studies were performed using a Bond-Max immunos-
tainer (Vision BioSystems, Hingham, MA) with polymer-
defined peroxidase detection.
Because no cutoff for positivity has been validated to
define TOP2A overexpression, we analyzed this variable
based on a cutoff of 20% or greater (mean value in this
study) and median values (10% of stained cells). The
Ki-67 positivity was defined as 20% or greater of stained
cells because the staining in our normal control breast
tissue (from the tissue bank of Hospital Clínico San Car-
los) was always lower than this value. The cut points for
ER and progesterone receptor positivity were established
at 10% or greater of stained cells. All tumors were graded
by the study pathologist (JALGA) by using Elston-Ellis
histological grading.27
Measurement of TOP2A and ERBB2
Amplification
The amplification of TOP2A and ERBB2 was measured by
FISH. The probes used were as follows: locus-specific
identifier TOP2A, labeled in orange; centromere enumer-
ation probe 17, labeled in green; and locus-specific iden-
tifier ERBB2 probe, labeled in orange (Vysis-Abbott,
Downers Grove, IL). Slides were prepared according to
cteristics by TOP2A Status
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(1.9) 0.86 0.01 (0.9) 0.76 12 0.11
(1.6) 0.06 (0.7) 13
(1.9) 0.71 0.11 (0.9) 0.60 8 1.0
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positive result was defined as an ERBB2 and TOP2A
genes/chromosome 17 ratio of 2.2 or greater (for ERBB2)
or greater than 2 (for TOP2A). The cutoff for the deletion
was established as a TOP2A gene/chromosome 17 ratio
of 0.5 or lower. Images were visualized on a fluorescence
microscope and captured on a workstation (MetaSys-
tems, Altlussheim, Germany). A minimum of 100 nuclei
were counted per case. All cut points were predefined
before the correlations were performed; in all of the
cases, the pathologist (JALGA) was blinded from the
patient’s identity and outcome.
Statistical Analysis
Qualitative variables were summarized by their frequency
distribution, and quantitative variables were summarized
by their mean  SD. The continuous values of Q-PCR
were log transformed. For qualitative variables, compar-
ison was evaluated by the 2 or Fisher exact test in cases
in which more than 25% of the expected values were less
than five. The association between the expression of
TOP2A, measured by gene expression microarrays or
Q-PCR, and other qualitative variables was assessed by
t-test. To compare between more than two groups, a
one-way analysis of variance for quantitative variables
was used. The correlation among the quantitative values
of TOP2A expression, measured by Q-PCR and gene
expression microarrays, was evaluated with simple linear
regression analysis. The comparison between TOP2A ex-
pression data, assessed by IHC, and gene expression
microarrays or Q-PCR was performed using receiver op-
erating characteristic curve analysis. The area under the
curve, sensitivity, and specificity were also determined.
The adjusted false-positive, false-negative, and error
rates of the determined cutoffs were estimated using a
bootstrapping method. Simple Cohen’s  coefficients
and percentage agreement with its 95% confidence in-
terval were used to assess the agreement when classi-
fying the tumors as TOP2A positive or TOP2A negative.
The strength of agreement is considered to be slight
when  values are between 0.00 and 0.20; fair, 0.21
and 0.40; moderate, 0.41 and 0.60; good, 0.61 and
0.80; and almost perfect, 0.81 and 1.00. All statistical
tests were two sided, and P  0.05 was considered
significant. The statistical analysis was performed us-
ing software (SPSS 17.0 and R 2.10.1).
Results
Clinicopathological Characteristics of the Study
Population
Table 1 summarizes the pathological characteristics of
the 61 tumor samples/patients and the distribution of
characteristics by TOP2A status. As shown, TOP2A copy
number alterations were significantly associated with tu-
mor size, stage, and ERBB2 amplification status. Inter-
estingly, TOP2A expression, as assessed by Q-PCR or
microarray, was not significantly associated with any ofthese characteristics. On the other hand, TOP2A sta-
tus, by Q-PCR and gene expression microarrays, was
significantly associated with Ki-67 positivity (P  0.008
and P  0.005, respectively). Similarly, according to
IHC data, TOP2A protein overexpression was more fre-
quent in Ki-67–positive tumors, although Ki-67 positivity
was not significantly associated with TOP2A IHC positiv-
ity (P  0.08).
In addition, we found that TOP2A mRNA expression, as
assessed by Q-PCR or gene expression microarrays,
varied significantly with intrinsic subtype (P  0.001 in
both cases). High-proliferative subtypes, such as Basal-
like, Luminal B, and Her2-enriched, expressed higher
levels of TOP2A than Luminal A, Claudin-low, or Normal-
like tumors (Figure 1, A and B). In the same way, accord-
ing to IHC data, the proportion of TOP2A-positive tumors
was statistically different depending on tumor subtype
(P  0.002). As shown in Figure 1C, Basal-like, Her2-
enriched, and Luminal B tumors had the most TOP2A-
positive tumors, whereas Luminal A tumors were mostly
TOP2A negative and all Normal-like tumors were TOP2A
negative. Therefore, TOP2A expression can be consid-
ered a proliferative marker that is highly characteristic of
the rapidly growing tumor subtypes. Finally, we observed
that TOP2A copy number alterations occurred in Luminal
A, Luminal B, Her2-enriched, and Claudin-low subtypes;
no alterations were found in Basal-like and Normal-like
tumors (Figure 1D).
Correlation Between TOP2A Status Assessed
by Q-PCR, Gene Expression Array, and IHC
The TOP2A expression values measured by Q-PCR and
gene expression microarrays significantly correlated with
each other (Pearson correlation coefficient, 0.816; 95% con-
fidence interval, 0.71 to 0.89; P  1.2  1015) (Figure 2).
In addition, tumors with positive TOP2A expression by
IHC had relatively higher mean levels of TOP2A expres-
sion, as measured by Q-PCR (P  0.002) or gene ex-
pression microarrays (P  0.001).
To demonstrate the concordance of TOP2A expression
status, determined by these techniques, we performed
receiver operating characteristic curve analysis to assess
how TOP2A gene expression by Q-PCR or microarrays
can predict TOP2A-positive status by IHC. For Q-PCR,
the area under the curve was 0.741 (sensitivity, 80%;
specificity, 72%; best cutoff value, 1.04; adjusted error
rate, 27%; adjusted false-positive rate, 23%; adjusted
false-negative rate, 30%); for gene expression microar-
rays, the area under the curve was 0.791 (sensitivity,
100%; specificity, 53%; best cutoff value, 0.48; ad-
justed error rate, 30%; adjusted false-positive rate, 4%;
adjusted false-negative rate, 49%) (Figure 3).
TOP2A Copy Number Alteration and TOP2A
Expression
The TOP2A was amplified in 13 cases (21.3%) and de-
leted in 2 cases (3.3%). Unlike RNA and protein levels, no
significant association was observed between TOP2A
P2A-positive and TOP2A-negative tumors, according to FISH, for each subtype. CNA
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measured by Q-PCR or gene expression microarrays.
In addition, we did not find agreement between IHC
and FISH when assessing TOP2A status in tumor sam-
ples (  0.134, P  0.26) (Table 2).
Discussion
In this study, TOP2A gene expression, as assessed by
DNA microarray or Q-PCR, was significantly associated
with Ki-67 IHC positivity. When TOP2A was assessed by
IHC, a similar tendency was observed. Taken together,
these data suggest that TOP2A expression across all
breast cancers is likely a proliferation marker, which is
concordant with previous reports about breast can-
cer28–30 and tumor types.31,32 Consistent with these
data, we found higher TOP2A gene expression in highly
proliferative subtypes, such as Basal-like, Luminal B, and
Her2-enriched tumors, when compared with Luminal A,
Normal-like, and Claudin-low tumors. Therefore, tumor
proliferation may have a confounding effect on the pre-
dictive value of TOP2A and, therefore, TOP2A expression
may possibly need to be adjusted for Ki-67 or other
Figure 1. A: Box plot. The TOP2A mRNA expression values, measured by g
mRNA expression values, measured by Q-PCR, according to genomic subty
tumors, according to IHC, for each subtype. D: Bar chart. The number of TO
indicates copy number alteration.proliferative markers.ene expression microarrays, according to genomic subtype. B: Box plot. The TOP2A
pe. C: Bar chart. The number of TOP2A-positive (POS) and TOP2A-negative (NEG)Figure 2. Correlation between TOP2A expression values, assessed by gene
expression microarrays and Q-PCR.
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cer is a heterogeneous disease, rather than a single
disease; and breast cancer subtypes have specific clin-
icopathological characteristics with different progno-
ses.24,25,33,34 The relative benefit of anthracyclines has
not been tested for each specific breast cancer molecu-
lar subtype, although therapeutic outcome might be af-
fected by molecular subtype.35 Different results among
researchers who have assessed the predictive value of
TOP2A expression might be, in part, because of different
proportions of breast cancer subtypes between study
populations; we demonstrated that TOP2A expression is
substantially different across the known subtypes.
In our study, TOP2A amplification was associated with
tumor size, stage, and ERBB2 positivity. Interestingly,
none of these characteristics was associated with TOP2A
expression. This might suggest that TOP2A protein–over-
expressing tumors and tumors with TOP2A copy number
alterations might be biologically different. Indeed, we
found that the distribution of TOP2A-amplified tumors
among subtypes is different and that the protein expres-
sion is also uniquely different; thus, it is not surprising to
find that the FISH and IHC data are not that highly cor-
Figure 3. Receiver operating characteristic curves. Prediction of TOP2A IHC
positivity according to gene expression microarrays and Q-PCR data.
Table 2. The TOP2A-Positive and TOP2A-Negative Tumors
According to FISH and IHC Results
FISH results
IHC results
 (P) value*Positive Negative
Positive 8 (13) 7 (11) 0.134 (0.26)
Negative 17 (28) 29 (48)
Data are given as number (percentage) of 61 tumors unless otherwise
indicated.
*Cohen’s  coefficient for agreement between FISH and IHC results.related. The expression of TOP2A has been extensively
studied in human breast cancers by different methods.
However, the correlation between techniques has been
scarcely reported. As expected, our results showed a
good correlation among Q-PCR and gene expression
microarrays (Pearson correlation coefficient, 0.816).
A threshold value for TOP2A expression that could
define subgroups associated with treatment outcome re-
mains to be established. Some researchers17,36–38 have
used an arbitrary IHC cutoff of greater than 10%, whereas
others39 have used a 25% cutoff. We used a cutoff of
20% because staining in our control healthy breast tissue
was always lower than this value; however, similar results
were obtained when considering the cutoff of 10% (data
not shown). We found that both microarrays and Q-PCR
predicted fairly well the TOP2A expression values mea-
sured by IHC. In addition, our results showed a signifi-
cant association between TOP2A mRNA and protein lev-
els. However, IHC is potentially a more subjective
technique and may have a lower precision when assess-
ing the status of TOP2A relative to Q-PCR. Interestingly,
no association between TOP2A copy number alterations
and the expression of the gene was observed, which is in
agreement with previous reports.17,40
Because TOP2A is considered the molecular target of
anthracyclines,3 the predictive value of this gene in pa-
tients with breast cancer has been widely studied. Sev-
eral retrospective studies12–16 have shown that ERBB2-
positive tumors are rather sensitive to anthracyclines. In
addition, amplification of ERBB2 is variable in size. Some
flanking genes in the 17q12-q21 region, such as TOP2A,
are frequently either coamplified or deleted in breast
cancers with ERBB2 amplification.41–43 Because of this
coincidence, many researchers have hypothesized that
TOP2A amplification might become the gold standard
predictive factor for anthracyclines, rather than ERBB2;
and many retrospective studies have been conducted to
assess its predictive value. However, although several
studies19,39,42,44 have shown that TOP2A alterations are
associated with an increased responsiveness to anthra-
cycline-containing regimens, others20,45 have been in-
conclusive.
Our data suggest that TOP2A amplification and TOP2A
overexpression are indicative of different biological pro-
cesses because these two events are not associated and
are characteristic of different tumor subtypes. For exam-
ple, Basal-like tumors typically overexpressed TOP2A
protein and/or mRNA, but no Basal-like tumor had TOP2A
DNA copy number changes. This might suggest that the
predictive value of TOP2A copy number may not be be-
cause of a TOP2A protein function. Rather, it may be
indicative of some other biological process or genomic
aberration that could be characteristic of ERBB2-ampli-
fied tumors because TOP2A amplification occurs almost
exclusively within ERBB2-amplified tumors. In support of
this hypothesis, a previous study,39 performed in a cohort
of 245 patients, found that TOP2A amplification predicted
benefit from adjuvant anthracyclines only in the subset of
ERBB2-positive breast cancer but failed to predict re-
sponse when the entire population of the study was con-
sidered. Similarly, the TOP trial showed that TOP2A am-
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amplification, predicted benefit from regimens containing
anthracyclines in ER-negative tumors.46 In both studies,
TOP2A expression did not correlate with treatment out-
come. Contrary to these results, we recently observed
that TOP2A expression is predictive of response to a
single agent, doxorubicin, but not TOP2A amplification.47
Because the target of anthracyclines is the TOP2A pro-
tein, not the gene, it seems that the study of the expres-
sion (RNA and protein) might predict more accurately the
treatment outcome with anthracyclines than TOP2A copy
number alterations (amplification or deletion); further
studies on this point are clearly warranted.
In summary, TOP2A copy number alterations do not
correlate with gene expression in breast cancers, and the
expression of the gene/protein varies significantly de-
pending on the tumor subtype and proliferation status.
These facts could explain, in part, the previously reported
discrepancies regarding the predictive value of TOP2A
for anthracycline-based chemotherapy regimens.
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